Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellgram-CLI
- Development stage
- Preclinical
- Lead developer
- Pharmicell
- Modality
- Bone Marrow MSCs → Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular (for Cli)
01
Overview
Cellgram-CLI is an autologous bone marrow-derived mesenchymal stem cell therapy developed by Pharmicell for the treatment of critical limb ischemia (CLI). The product consists of mesenchymal stem cells isolated from a patient's own bone marrow, expanded ex vivo, and administered via intramuscular injection. The mechanism of action is based on the regenerative, immunomodulatory, and angiogenic properties of mesenchymal stem cells, which can promote tissue repair and neovascularization in ischemic limbs. This approach aims to improve blood flow, reduce pain, enhance wound healing, and decrease the risk of major amputation in patients with CLI who have limited revascularization options. Clinical studies with similar autologous bone marrow-derived cell therapies have demonstrated safety and potential efficacy in improving outcomes for CLI patients[8].
- Brand names
- Cellgram-CLI
- Other names
- Cellgram-CLI
Beyond the preview
Go deeper on Cellgram-CLI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellgram-CLI.